Comparison · NCT02867813-sae
Evolocumab in Parent Study vs Placebo in Parent Study: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Evolocumab in Parent Study vs Placebo in Parent Study: serious adverse events. Trial comparisons, record NCT02867813-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02867813-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.418 | 0.399 | 0.438 | wilson | |
| Risk in group 2 | 0.425 | 0.406 | 0.445 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00719 | -0.0345 | 0.0201 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.983 | 0.921 | 1.05 | log | |
| Odds ratio, group 1 over group 2 | 0.971 | 0.868 | 1.09 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Evolocumab in Parent Study than on Placebo in Parent Study | 139 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Evolocumab in Parent Study | Participants with Evolocumab in Parent Study | 1,045 | 2,499 | EG001 |
| Group 2 | Placebo in Parent Study | Participants with Placebo in Parent Study | 1,077 | 2,532 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Day 1 up to approximately 5 years during the OLE study.
Source ClinicalTrials.gov
Trial
- Title
- Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension
- NCT number
- NCT02867813
- Phases
- PHASE3
- Conditions
- Dyslipidemia
- Interventions
- Evolocumab
- Lead sponsor
- Amgen
- Results first posted
- 2023-02-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02867813?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02867813-sae